IMPACT BIOMEDICAL INC.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

IBO$4.33+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

	Impact BioMedical, Inc.
March 11, 2026	By:	/s/ Frank D. Heuszel
		Frank D. Heuszel
		Chief Executive Officer
		(Principal Executive Officer)

March 11, 2026	By:	/s/ Todd D. Macko
		Todd D. Macko
		Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

March 11, 2026	By:	/s/ Frank D. Heuszel
		Frank D. Heuszel Chief Executive Officer (Principal Executive Officer)
March 11, 2026	By:	/s/ Todd D. Macko
		Todd D. Macko
		Chief Financial Officer (Principal Financial and Accounting Officer)
March 11, 2026	By:	/s/ Mark Suseck
		Chief Operating Officer
March 11, 2026	By:	/s/ Jason Grady
		Jason Grady Director
March 11, 2026	By:	/s/ Elise Brownell
		Elise Brownell Director
March 11, 2026	By:	/s/ Melissa Sims
		Melissa Sims Director
March 11, 2026	By:	/s/ Castel Hibbert
		Castel Hibbert
		Director
March 11, 2026	By:	/s/ Christian Zimmerman
		Christian Zimmerman Director
March 11, 2026	By:	/s/ David Keene
		David Keene
		Director

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.